Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

combination with other approved cancer drugs. ENMD-2076 is unique-in-class because it not only inhibits Aurora A selectively, it also inhibits a cluster of kinases that are important for tumor growth, particularly growth factor receptors critical to angiogenesis. ENMD-2076 has potent antitumor activity in multiple preclinical models, including both solid tumors and hematological cancers."

James S. Burns, EntreMed President & Chief Executive Officer commented, "Further development of ENMD-2076 is consistent with both our focus on investing behind oncology drug candidates with strong single-agent activity and our continuing interest in kinase inhibitors. In keeping with our 2008 goals of cash preservation and rigorous resource management, we intend to pay the $2 million Phase 1 milestone to Miikana shareholders in shares of EntreMed common stock. Our goals for this program over the next twelve months are to complete the clinical trial in solid tumor patients, initiate a clinical trial in patients with hematological cancers, and secure a pharmaceutical partner to help accelerate the development of ENMD-2076."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at '/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 Research and Markets ( ... "2015 Global Survey on Flow Cytometry Adoption ... The primary goal of this research is to ... reagents. Key information the survey seeks to collect ... cytometers, predominantly used applications for flow cytometers, respondents, ...
(Date:5/20/2015)... 20, 2015 Research and Markets ( ... "Top Technologies in HW_Technical Insights" report to their ... evaluated technology trends in the Health and Wellness sector ... to have an impact in the year 2015. The ... top 10 health and wellness technologies that are anticipated ...
(Date:5/20/2015)... May 20, 2015  Health eCareers, the healthcare ... organizations with job seekers looking for the flexibility ... new mobile and online tool dedicated exclusively to ... SHIFT enables employers to quickly find ... nursing, per diem and other temporary positions, eliminating ...
(Date:5/20/2015)... , May 20, 2015  Resolution Bioscience announced ... ctDx ALK TM , a blood-based liquid biopsy ... cell lung carcinoma (NSCLC), the most common form of ... test to guide patients to personalized therapies and direct ... The Department of Health, the CLIA authority ...
Breaking Biology Technology:Global Survey on Flow Cytometry Adoption Trends 2015 2Top Technologies in the Health and Wellness Industry 2015 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... Aesculap AG, Introduces MonoMax(R) Monofilament Suture at the German ... CE Mark LEXINGTON, Mass., May 1 Tepha, ... its corporate partner, Aesculap AG, has received a CE ... for general surgical indications in Europe. The product ...
... 15, 2009 at 8:00 am (Eastern) / 5:00 am ... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... outsourcing company with operations in China and the United ... for the first quarter of 2009 on May 15, ...
... NeurogesX, Inc. (Nasdaq: NGSX ), a ... management therapies, today announced it will hold a conference ... ET (1:30 p.m. PT) to report results for its ... by Anthony DiTonno, President and Chief Executive Officer, and ...
Cached Biology Technology:Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tepha's Proprietary Biomaterial 2Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tepha's Proprietary Biomaterial 3WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release 2NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results 2NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results 3
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... cells is dictated by the speed of movement (diffusion) of ... developed at the Institute of Physical Chemistry of the Polish ... for the first time the diffusion coefficients of all proteins ... only for biologists and chemists, but also for... transport companies. ...
... congenital sight impairment caused by lens damage is closer following ... Barberi and Dr Isabella Mengarelli from the Australian Regenerative Medicine ... the human eye in the lab. They have, for the ... tissue from which the lens of the eye develops. The ...
... the diagnosis and treatment of cancers in recent years ... survival rates. While doctors can treat the physical ... to address the psychological needs of patients with cancer. ... associated with cancer, many patients also experience psychologically harmful ...
Cached Biology News:Biologistics: How fast do chemical trains move in living cells? 2Biologistics: How fast do chemical trains move in living cells? 3'Petri dish lens' gives hope for new eye treatments 2The potential of psilocybin to alleviate psychological distress in cancer patients is revealed 2
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
... raised against a partial recombinant ... SLC22A3 (NP_068812, 90 a.a. ... protein with GST tag. ... NM_021977 Protein ...
... UniPrimer-fluorescein is a hairpin primer labeled ... (fluorescein and non-fluorescent quencher) and a ... UniPrimer is identical to the UniPrimer ... System (S7901) and is provided at ...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Biology Products: